In vitro and in vivo evaluation of 64Cu-radiolabeled kccysl peptides for targeting epidermal growth factor receptor-2 in breast carcinomas

Senthil R. Kumar  
*University of Missouri Columbia*

Fabio A. Gallazzi  
*University of Missouri Columbia*

Riccardo Ferdani  
*Washington University School of Medicine in St. Louis*

Carolyn J. Anderson  
*Washington University School of Medicine in St. Louis*

Thomas P. Quinn  
*University of Missouri Columbia*

*See next page for additional authors*

Follow this and additional works at: [http://digitalcommons.wustl.edu/open_access_pubs](http://digitalcommons.wustl.edu/open_access_pubs)

Recommended Citation
[http://digitalcommons.wustl.edu/open_access_pubs/2804](http://digitalcommons.wustl.edu/open_access_pubs/2804)
Authors
Senthil R. Kumar, Fabio A. Gallazzi, Riccardo Ferdani, Carolyn J. Anderson, Thomas P. Quinn, and Susan L. Deutscher
In Vitro and In Vivo Evaluation of $^{64}$Cu-Radiolabeled KCCYSL Peptides for Targeting Epidermal Growth Factor Receptor-2 in Breast Carcinomas

Senthil R. Kumar,1,2 Fabio A. Gallazzi,3 Riccardo Ferdani,4 Carolyn J. Anderson,4 Thomas P. Quinn,1 and Susan L. Deutscher1,2

Abstract

Epidermal growth factor receptor-2 (EGFR-2) has been implicated in the pathogenesis of breast and other carcinomas. In this report, we tested the ability of a bacteriophage selected peptide KCCYSL, radiolabeled with $^{64}$Cu, to image EGFR-2 expressing breast tumors in vivo by positron emission tomography (PET). We evaluated and compared the in vivo tissue distribution and imaging properties of $^{64}$Cu-X-(Gly-Ser-Gly)-KCCYSL peptide ($X = 1,4,7,10$-tetraazacyclododecane-$N,N',N'',N'''$-tetracetic acid, [DOTA] 1,4,8,11-tetraazabicyclo[6.6.2] hexadecane-4,11-diacetic acid [CB-TE2A], and 1,4,7-triazacyclononane-1,4,7-triacetic acid [NOTA] chelators) in a human breast cancer xenograft mouse model using dual modality PET and computed tomography (CT). The synthesized peptides DO3A-GSG-KCCYSL, CB-TE2A-GSG-KCCYSL, and NO2A-GSG-KCCYSL were purified, radiolabeled with $^{64}$Cu, and evaluated for human breast cancer cell (MDA-MB-435) binding, 50% inhibitory concentration, and serum stability. In vivo pharmacokinetic and small animal PET/CT imaging studies were performed using SCID mice bearing MDA-MB-435 xenografts. The radiolabeled peptides bound with an 50% inhibitory concentration of 42.0 ± 10.2 nM (DO3A), 31 ± 7.9 nM (CB-TE2A), and 44.2 ± 6.6 nM (NO2A) to cultured MDA-MB-435 cells. All of the radiolabeled peptides were stable in vitro. The tumor uptake of DO3A, CB-TE2A, and NO2A peptides were 0.73 ± 0.15 percent injected dose per gram (%ID/g), 0.64 ± 0.08%ID/g, and 0.52 ± 0.04%ID/g, respectively at 1 hour. Liver uptake for the $^{64}$Cu-DO3A-peptide (1.68 ± 0.42%ID/g) was more than that of the $^{64}$Cu-CB-TE2A-peptide (0.52 ± 0.02% ID/g) and $^{64}$Cu-NO2A-peptide (0.48 ± 0.05%ID/g) at 2 hours. PET/CT studies revealed successful tumor uptake of $^{64}$Cu-peptides at 2 hours postinjection. In vivo kidney retention was observed with all of the radiolabeled peptides. The optimization of bifunctional chelators improves the pharmacokinetic properties of the $^{64}$Cu-labeled GSG-KCCYSL peptide, which enables the selection of a suitable peptide homolog as a PET imaging agent for EGFR-2 expressing breast carcinomas.

Key words: breast cancer, $^{64}$Cu-chelators, EGFR-2, peptide, PET-imaging

Introduction

Epidermal growth factor receptor-2 (EGFR-2, erythroblastic leukemia viral oncogene homolog 2 [ErbB-2]) is a member of the EGFR family of transmembrane receptor tyrosine kinases.1,2 EGFR-2 expression has been reported to be minimal in normal tissues,3 however, amplification of this receptor occurs in approximately 30% of invasive breast cancers and is associated with poor patient outcome.4–6 Hence, EGFR-2 has been identified as a target for cancer
imaging and therapy. In the past few years, several groups have developed antibodies, scFV fragments, and peptides\textsuperscript{2,10} that bind to EGFR-2.

Bacteriophage (phage) display libraries have been extensively used to identify peptides that bind to a variety of targets including EGFR-2.\textsuperscript{11-13} Such phage-derived peptides, once radiolabeled, hold promise as effective imaging agents for identifying specific human tumors and evaluating response to therapy. Although many imaging agents have been developed using antibodies and proteins, they often demonstrate low specificity, poor accumulation in target tissue, sensitivity to reaction conditions, and slow clearance properties in vivo.\textsuperscript{14,15} Accordingly, the number of radiopharmaceuticals utilizing bifunctional chelator-conjugated peptides for use in imaging has grown considerably over the past few decades.\textsuperscript{16,17} Previously, we reported an \textsuperscript{111}In-labeled phage display selected peptide, KCCYS1, for single photon emission computed tomography (SPECT) imaging of EGFR-2 expressing human breast tumor xenografts in mice.\textsuperscript{18} However, due to the inherent limited sensitivity and resolution of SPECT imaging, we were interested in evaluating KCCYS1 peptide for the positron emission tomography (PET) targeted imaging of EGFR-2 expressing tumor(s).

PET imaging depends on the delivery of a targeting ligand containing a positron emitting radionuclide to a tissue or organ of interest. Copper-64 (t\textsubscript{1/2} = 12.7 hours) is an attractive radionuclide for PET imaging that can be used for both diagnostic imaging and radionuclide therapy due to its dual decay characteristics.\textsuperscript{19} The positron emissions (\(\beta^+ = 17.8\%\), E\textsubscript{\beta^+} = 553 keV; \(\beta^- = 38.4\%\), E\textsubscript{\beta^-} = 578 keV) would allow clinicians to image a patient using PET and provide therapeutic treatment using the same \textsuperscript{64}Cu-targeted pharmaceutical. Unfortunately, the application of \textsuperscript{64}Cu-based radiopharmaceuticals has been hindered by the lack of stable copper radiotracers in vivo. The high uptake and retention of copper-containing compounds in the blood and liver are well known.\textsuperscript{20,21} Therefore, more stable chelator-compounds are necessary for in vivo studies using \textsuperscript{64}Cu.

Macroyclic polyamine complexes of 1,4,8,11-tetraaza-cyclooctadecane-N,N',N'',N'''-tetracetic acid (TETA) and 1,4,7,10-tetraazaclodecane-N,N',N'',N'''-tetracetic acid (DOTA) with copper have been shown to exhibit greater kinetic inertness than acyclic analogs, but dissociation of copper from both the chelators occurs in vivo.\textsuperscript{22-24} Weisman, Wong, and Anderson designed and characterized the novel cross-bridged tetraaza-macroyclic chelator 1,4,8,11-tetraazaabicyclo[6.6.2]hexadecane-4,11-diacetic acid (CB-TE2A) and demonstrated enhanced in vivo stability with significantly less transchelation in the liver compared with \textsuperscript{64}Cu-TETA. Thus, the rigidity of the cross-bridge system was credited for the greater kinetic stability of the copper (II)-CB-TE2A complex.\textsuperscript{25,26}

Previous studies have also demonstrated the use of 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), a 9-member cyclic chelating agent for divalent copper.\textsuperscript{27-29} NOTA was shown to have the capacity to form stable metal complex with Cu\textsuperscript{2+} and other divalent and trivalent metals,\textsuperscript{27,28} which overcome demetallation and tracer uptake in tissues such as liver. Functionalized NOTA derivatives suitable for conjugation with proteins or peptides have been reported by different groups.\textsuperscript{29,30} In this study, we evaluated and compared the in vitro and in vivo properties of DO3A-GSG-KCCYS1, CB-TE2A-GSG-KCCYS1, and NO2A-GSG-KCCYS1 radiolabeled with \textsuperscript{64}Cu. The radiolabeled peptides were tested for cell binding, stability, pharmacokinetics, and tumor imaging in MDA-MB-435 human breast carcinoma xenografted mice using small-animal PET/CT.

Materials and Methods

Reagents, cell lines, and animals

Reverse phase-high performance liquid chromatography (RP-HPLC)–grade acetonitrile, and trifluoroacetic acid were purchased from Fischer Scientific for HPLC analysis. Copper-64 was purchased from Nuclear Reactor Laboratory, University of Wisconsin. RPMI (Roswell Park Memorial Institute) 1640 and human mammary epithelial cell media were purchased from Invitrogen/Gibco. Bovine serum albumin (BSA) and trypsin were obtained from Sigma Chemical Company. DOTA was purchased from Macrocyclcs, and CB-TE2A was synthesized as previously described.\textsuperscript{31} NOTA was procured from Chematech.

Normal mammary 184A1 cell line was obtained from American Type Tissue Culture. The MDA-MB-435 cells were maintained as monolayer cultures in RPMI-1640 medium supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential amino acids, and l-glutamine. 184A1 cells were grown in (human mammary epithelial cell) media supplemented with bovine pituitary extract. Cell cultures were maintained at 37 °C in a 5% CO\textsubscript{2} humidified incubator. Sub-culturing was performed using standard trypsinization procedures.

Four- to 5-week-old ICR-SCID (Institute of Cancer Research severely compromised immunodeficient) female mice were obtained from Taconic Farms. The mice were supplied with sterilized water and irradiated rodent chow ad libitum. Under gas anesthesia, each SCID mouse was subcutaneously inoculated in the right shoulder with 1 \times 10\textsuperscript{5} MDA-MB-435 cells. The tumors were allowed to grow for 3–4 weeks before studies were performed. Animal studies were conducted in accordance with the protocols approved by the institutional animal care and use committee in accordance with U.S. Public Health Service guidelines.

Solid-phase peptide synthesis

Peptides used in this study were synthesized using an Advanced Chem Tech 396 multiple peptide synthesizer (AAPPTEC) using standard Fmoc chemistry. Briefly, the resin (50 μmol) was deprotected using piperidine, resulting in the formation of a primary amine from which the C-terminus of the growing peptide was anchored. The Fmoc protected amino acids (225 μmol) with appropriate orthogonal protection were activated using O-benzotriazole-N,N,N',N''-tetramethyl-uronium-hexafluoro-phosphate, N-hydroxybenzotriazole, and N,N'-disopropylethylamine and sequentially added to the resin. The metal chelators DOTA or NOTA were coupled to the amino terminus of the linear GSG-KCCYS1 complex. In the case of CB-TE2A, the chelator was coupled to the peptide on the resin through an intermediate preparation of the activated mixed anhydride by use of disopropylcarbodiimide/ N,N'-disopropylethylamine/dimethylformamide as described earlier.\textsuperscript{31} The resulting peptide was deprotected and cleaved from the resin using a cocktail consisting of thionaisol, water,
Radiolabeling of peptides with $^{64}\text{Cu}$

Radiolabeling of DO3A-, CB-TE2A-, or NO2A-(GSG)-KCCYSL with $^{64}\text{Cu}$ was performed as follows: For DO3A-(GSG)-KCCYSL, the peptide (50 $\mu$g) was radiolabeled with 29.6 MBq $^{64}\text{Cu}$ in 80 $\mu$L ammonium acetate (0.1 M) pH 5.5, at 85°C for 90 minutes. Similarly, CB-TE2A-(GSG)-KCCYSL (50 $\mu$g) was radiolabeled with 29.6 MBq $^{64}\text{Cu}$ in ammonium acetate (0.4 M) pH 7.0, at 85°C for 90 minutes, and NO2A-(GSG)-KCCYSL (50 $\mu$g) was radiolabeled with 29.6 MBq $^{64}\text{Cu}$ in ammonium acetate (0.4 M) pH 6.8, at 75°C for 60 minutes. The reaction buffer was purged with nitrogen before radiolabeling to inhibit or minimize peptide oxidation. Also, as a precautionary measure, the reaction buffers contained 0.05 mM Tris- (2-carboxyethyl) phosphine hydrochloride (TCEP.HCl) to maintain cysteine reduction in the wake of radiolabeling to inhibit or minimize peptide oxidation. Also, as a precautionary measure, the reaction buffers contained 0.05 mM Tris- (2-carboxyethyl) phosphine hydrochloride (TCEP.HCl) to maintain cysteine reduction in the wake of radiolabeling to inhibit or minimize peptide oxidation.

Preparation of native Cu-peptides ($^{64}\text{Cu}$)

For nonradioactive Cu-labeling, 0.5 mg samples of DO3A-(GSG)-KCCYSL, CB-TE2A-(GSG)-KCCYSL, and NO2A-(GSG)-KCCYSL peptides were dissolved separately in 500 $\mu$L ammonium acetate buffer (pH 5.5). The solutions were heated at identical conditions used for radiolabeling procedure and allowed to cool to room temperature. Final Cu-peptides were then purified by RP-HPLC. The purified Cu-peptides were detected by electrospray ionization mass-spectrometry to check the integrity of the peptides.

In vitro cell binding of radiolabeled KCCYSL peptides

Experiments were performed to test the ability of the radiolabeled peptides to bind cell lines that express low to moderate levels of EGFR-2 (MDA-MB-435) or normal mammary epithelial cells (MCF-10A) with negligible EGFR-2 expression. Cells grown in culture flasks were trypsinized, released, and washed once in cell binding media (RPMI 1640 with 25 mM HEPES, pH 7.4, 0.2% BSA, 3 mM 1, 10-phenanthroline). Cells (1 x 10^6 cells/tube) were incubated with microcentrifuge tubes containing 0.5 mL cell binding medium and were incubated at 37°C for different times (15 minutes, and 0.5, 0.75, 1, 1.5 and 2 hours) with 1 x 10^7 counts per minute (cpm) of radiolabeled peptides. After incubation, the media were removed, and the cells were rinsed with ice-cold 0.01 M PBS, pH 7.4, 0.2% BSA, and centrifuged. This process was repeated twice. Radioactivity bound to the cells was quantified in a Wallac γ counter (PerkinElmer Life and Analytical Sciences Inc.). Cell binding ability was reported as total radioactivity in cpm that was bound to the cells.

Fifty-percent inhibitory concentration (IC50) binding studies for radiopeptides were performed using cultured MDA-MB-435 breast carcinoma cells. For competitive binding assays, MDA-MB-435 cells (2.5 x 10^6 cells/tube) were incubated with 2.5 x 10^4 cpm $^{64}\text{Cu}$-DO3A or $^{64}\text{Cu}$-CB-TE2A or $^{64}\text{Cu}$-NO2A peptide and increasing concentrations of their respective nonradioactive $^{64}\text{Cu}$-peptide counterparts (10^-12-10^-5 M) (n = 3 each). The cell-associated radioactivity was measured in a Wallac γ counter, and the binding affinity was determined by the Grafit software program (Erithacus Software Limited).

In vitro serum stability of the radiolabeled peptides was tested by incubating 29.6 MBq of the respective peptide in 0.3 mL of mouse serum at 37°C for 0.5, 1, 2, 4, and 24 hours, respectively. At various time points, 40 $\mu$L aliquots were removed, and the proteins were precipitated with 40 $\mu$L acetonitrile. The samples were centrifuged at 12,500 rpm for 5 minutes, and the cleared lysate (~40 $\mu$L aliquots) was analyzed by RP-HPLC with a 0%-95% gradient acetonitrile in 30 minutes to assess the integrity of the radiolabeled peptides.

Pharmacokinetic studies of $^{64}\text{Cu}$-labeled peptides in MDA-MB-435 xenograft SCID mice

SCID mice bearing MDA-MB-435 tumors (3 per time point) were injected with approximately 0.185 MBq of different radiolabeled peptides and were sacrificed by cervical dislocation at 30 minutes and 1, 2, 4, and 24 hours postinjection (p.i.), after which tissues and organs of interest were collected. Gastrointestinal tract contents were not removed. The animal, tissue, and organ samples were weighed, and counts were determined with an automated γ counter. Uptake of radioactivity in the tumor and normal tissues and organs was expressed as a percentage of the injected radioactive dose per gram (%ID/g). Whole blood %ID or %ID/g was determined assuming the blood accounted for 6.5% of the body weight of the mouse. For blocking experiments, the MDA-MB-435 breast tumor-bearing mice (n = 3) were preinjected with 100 $\mu$g of $^{64}\text{Cu}$-DO3A or $^{64}\text{Cu}$-CB-TE2A or $^{64}\text{Cu}$-NO2A peptides. After 10 minutes p.i., of the nonradioactive peptide, 0.185 MBq of radiolabeled counterpart was injected and the blocking efficiency was evaluated after 2 hours.

For reducing the kidney retention of the radiolabeled peptides in mice, inhibition experiments with albumin fragments were performed. Briefly, 335 mg of trypsin was added to 3.0 g of BSA in 50 mM ammonium carbonate (15 mL). The mixture was incubated at 37°C for 24 hours. The trypsin-digested sample was filtered using 50 kDa Centriprep (YM-50) centrifugal filters (Millipore). The filtrate containing...
albumin fragments <50 kDa was further fractionated using a YM-3 filter (3 kDa cutoff), which yielded albumin fragments <3 kDa (filtrate) and fragments with molecular weight range of 3–50 kDa (residue). The effect of inhibition on renal uptake of the radiolabeled peptides was tested in the presence of the 3–50 kDa albumin fraction.

In separate experiments, the 3–50 kDa albumin fragment (200 μg) sample in normal saline (100 μL) was preinjected into the MDA-MB-435 tumor-bearing mice (n = 3) via the tail vein. After 5 minutes, 0.185 MBq of 64Cu-DO3A-(GSG)-KCCYSL or 64Cu-CB-TE2A-(GSG)-KCCYSL or 64Cu-NO2A-(GSG)-KCCYSL was administered into the mice. The mice were sacrificed after 2 hours p.i., and the kidney uptake of the radiolabeled peptides was measured in a γ-counter. Control experiments (n = 3) were run in parallel with pre-injection of normal saline instead of albumin fragments.

**MicroPET/CT imaging studies**

In vivo microPET/CT of MDA-MB-435 tumor-bearing mice with the radiolabeled peptides were performed as follows. MDA-MB-435 tumor-bearing mice were injected in the tail vein with 12.0 MBq of 64Cu-DO3A-(GSG)-KCCYSL or 64Cu-CB-TE2A-(GSG)-KCCYSL or 64Cu-NO2A-(GSG)-KCCYSL and imaged at 2 hours p.i., in a small animal PET scanner (MOSAiC small animal PET unit [Philips]). This PET scanner has a transverse field of view of 12.8 cm and a gantry diameter of 21 cm. The scanner operates in a three-dimensional (3D) mode. The mouse to be imaged was laser aligned at the center of the scanner field of view for imaging. The microPET image reconstruction was performed with a 3D row-action maximum-likelihood algorithm. Small animal CT was performed for the purpose of anatomic/molecular data fusion, and concurrent image reconstruction was performed with a Fanbeam (Feldkamp) filtered-backprojection algorithm. Reconstructed Digital Imaging and Communication in Medicine PET images were imported into AMIRA 3.1 software (Visage Imaging, Inc.) for subsequent image fusion with microCT and 3D visualization.

**Statistical analysis**

The data are presented as mean ± standard deviation. For statistical analysis, a Student’s t-test was performed using Prism software (Graphpad Software). A p-value ≤0.05 was considered significant.

**Results**

**Preparation and characterization of different chelator-KCCYSL peptide**

The peptides DO3A-(GSG)-KCCYSL, CB-TE2A-(GSG)-KCCYSL, and NO2A-(GSG)-KCCYSL were synthesized by solid-phase synthesis with GSG spacers between the chelators and the amino termini of the peptides to avoid possible steric hindrances. The chemical structures of different chelator-peptides are shown in Figure 1. Nonradioactive Cu-chelator-peptides were prepared by heating aqueous solutions of the peptides with CuSO4·5H2O at temperatures similar to those described for radioactive peptides. Nonradiolabeled copper-labeled peptides were purified and analyzed by mass spectrometry before cell binding assays. The calculated and observed molecular weight of 64Cu-peptide was 1365.0, 1364.7, 1302.0, 1301.8, and 1325.8 (DO3A-peptide), 1326.0 (CB-TE2A-peptide), and 95.2 ± 0.48%ID of 64Cu-CB-TE2A-peptide and 96.05 ± 0.15%ID of 64Cu-NO2A-peptide conjugate, respectively. Overall clearance of all the 64Cu-chelated peptides proceeded primarily through the renal system, with ~2.4 ± 0.36%ID (64Cu-DO3A-peptide), 0.54 ± 0.05%ID (64Cu-CB-TE2A-peptide), and 0.48 ± 0.07%ID (64Cu-NO2A-peptide) being excreted through the hepatobiliary system.

**Biodistribution and imaging studies**

Detailed in vivo pharmacokinetic studies with all the radiolabeled peptides in SCID mice bearing MDA-MB-435 xenografts were performed and are summarized in Tables 2–4. At 2 hours p.i., 89.4 ± 3.6%ID had been excreted from the mice using 64Cu-DO3A-peptide conjugate in comparison with 95.2 ± 0.48%ID of 64Cu-CB-TE2A-peptide and 96.05 ± 0.15%ID of 64Cu-NO2A-peptide conjugate, respectively. Overall clearance of all the 64Cu-chelated peptides proceeded primarily through the renal system, with ~2.4 ± 0.36%ID (64Cu-DO3A-peptide), 0.54 ± 0.05%ID (64Cu-CB-TE2A-peptide), and 0.48 ± 0.07%ID (64Cu-NO2A-peptide) being excreted through the hepatobiliary system.
The disappearance of different radiolabeled peptides from the blood was comparable at initial time points (0.5, 1, and 2 hours) tested. For instance, at the end of 2 hours p.i., peptide retention in the blood was 0.20 ± 0.08%ID/g, 0.05 ± 0.01%ID/g, and 0.08 ± 0.01%ID/g for ⁶⁴Cu-DO3A-, ⁶⁴Cu-CB-TE2A-, and ⁶⁴Cu-NO2A-peptides, respectively. Despite lower blood values observed for CB-TE2A and NO2A peptides compared with DO3A-peptide at or beyond 2 hours time point, the values were not statistically different (p > 0.05).

Unstable copper compounds are known to exhibit higher retention in the liver in vivo. In this study, the retention of ⁶⁴Cu in the liver with ⁶⁴Cu-DO3A-peptide was observed to be higher than ⁶⁴Cu-CB-TE2A- or ⁶⁴Cu-NO2A-peptide at all time points, suggesting the relative stable chelation of ⁶⁴Cu with CB-TE2A and NO2A. The difference in radiolabeled uptake in the liver between ⁶⁴Cu-DO3A- and ⁶⁴Cu-CB-TE2A-peptide (n = 3, p = 0.001), ⁶⁴Cu-DO3A-, and ⁶⁴Cu-NO2A-peptide (n = 3, p = 0.03) was statistically different, whereas the uptake between ⁶⁴Cu-NO2A- and ⁶⁴Cu-CB-TE2A-peptide was comparable and not statistically significant (n = 3, p > 0.05).

The tumor uptake of the ⁶⁴Cu-labeled peptides was comparable at 0.5 hours p.i. (0.91 ± 0.12%ID/g, ⁶⁴Cu-DO3A-peptide),

---

**Table 1. Characterization of ⁶⁴Cu Labeled Peptides**

<table>
<thead>
<tr>
<th>Peptide</th>
<th>RP-HPLC (t_r-min)</th>
<th>Labeling yield (%)</th>
<th>Radiochemical purity</th>
<th>Receptor affinity (IC₅₀, nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>⁶⁴Cu-DO3A-GSG-KCCYSL</td>
<td>12.8</td>
<td>55</td>
<td>≥98</td>
<td>42 ± 10.2</td>
</tr>
<tr>
<td>⁶⁴Cu-CB-TE2A-GSG-KCCYSL</td>
<td>13.3</td>
<td>45</td>
<td>≥98</td>
<td>31 ± 7.9</td>
</tr>
<tr>
<td>⁶⁴Cu-NO2A-GSG-KCCYSL</td>
<td>13.0</td>
<td>57</td>
<td>≥98</td>
<td>44 ± 6.6</td>
</tr>
</tbody>
</table>

The IC₅₀ was determined using corresponding nonradiolabeled counterparts. Details are given in Materials and Methods section.

IC₅₀ 50% inhibitory concentration; RP-HPLC, Reverse phase-high performance liquid chromatography.
FIG. 2. Epidermal growth factor receptor-2 receptor binding properties of the radiolabeled $^{64}$Cu-DOTA-(GSG)-KCCYS, $^{64}$Cu-CB-TE2A-(GSG)-KCCYS, and $^{64}$Cu-NO2A-(GSG)-KCCYS peptides. Approximately, $1.0 \times 10^5$ MDA-MB-435 breast carcinoma or normal mammary epithelial cells/tube were incubated at 37°C for different time intervals with 100,000 counts per minute radioligand. The radiolabeled peptides bound to human MDA-MB-435 breast carcinoma cells. $^{64}$Cu-DOTA-peptide (●); $^{64}$Cu-CB-TE2A-peptide (■) and $^{64}$Cu-NO2A-peptide (□). Very minimal or no binding was observed with normal mammary epithelial (184A1) cells using $^{64}$Cu-DOTA-peptide (▲) or $^{64}$Cu-CB-TE2A-peptide (●) or $^{64}$Cu-NO2A-peptide (○), respectively.

(0.98 ± 0.31%ID/g, $^{64}$Cu-CB-TE2A-peptide), and (0.78 ± 0.03%ID/g, $^{64}$Cu-NO2A-peptide). Also, in the later time points, there were no significant differences in the tumor uptake between the three radiolabeled peptides. For instance, at the 2 hours time point, the tumor uptake of $^{64}$Cu-DOTA-peptide was 0.54 ± 0.06%ID/g compared with that of 0.32 ± 0.08%ID/g for $^{64}$Cu-CB-TE2A and 0.61 ± 0.06%ID/g for $^{64}$Cu-NO2A-peptide, respectively.

The tumor-to-blood ratio was found to be significantly different between $^{64}$Cu-DOTA/ $^{64}$Cu-CB-TE2A peptides ($n = 3$, $p = 0.04$) and $^{64}$Cu-DOTA/$^{64}$Cu-NO2A peptides ($n = 3$, $p = 0.045$), whereas there was no significant difference between $^{64}$Cu-CB-TE2A/$^{64}$Cu-NO2A peptides for all time points ($p > 0.05$). Similarly, tumor-to-liver ratios were also significantly different between $^{64}$Cu-DOTA/$^{64}$Cu-CB-TE2A ($n = 3$, $p = 0.027$) and $^{64}$Cu-DOTA/$^{64}$Cu-NO2A ($n = 3$, $p = 0.01$) peptides, respectively. These results suggest that $^{64}$Cu-DOTA-peptide uptake in the liver was high compared with $^{64}$Cu-CB-TE2A and $^{64}$Cu-NO2A peptides. However, no major difference was observed between $^{64}$Cu-CB-TE2A and $^{64}$Cu-NO2A peptides, suggesting their uptake was comparable in liver tissue at all time points. No variation in tumor-to-muscle ratio was observed between the three radiolabeled peptides (Tables 2–4), and the differences in values were not statistically significant ($n = 3$, $p > 0.05$). Increased tumor-to-liver tissue ratio of both $^{64}$Cu-CB-TE2A and $^{64}$Cu-NO2A peptides compared with $^{64}$Cu-DOTA peptide suggests less transchelation of $^{64}$Cu from the former two chelator-peptides.

The retention of radiolabeled peptides was observed to be high in kidneys. Radioactivity in the kidneys decreased from 6.37 ± 1.44%ID/g at 0.5 hours to 4.27 ± 0.84%ID/g at 2 hours and 1.49 ± 0.24%ID/g at 24 hours, for $^{64}$Cu-DOTA-peptide. Similarly, the radioactivity declined from 7.11 ± 0.75%ID/g after 0.5 hours p.i., to 6.43 ± 1.56%ID/g at 2 hours, and 3.2 ± 0.23%ID/g at 24 hours for $^{64}$Cu-CB-TE2A peptide. $^{64}$Cu-NO2A-peptide uptake in kidneys was 7.87 ± 0.96 at 0.5 hours, which declined to 4.23 ± 1.00 at 2 hours, and 0.68 ± 0.07 at 24 hours. Further statistical comparison of

**Table 2. Pharmacokinetic Studies of $^{64}$Cu-DOTA-GSG-KCCYS Using MDA-MB-435 Tumor-Bearing SCID Mice**

<table>
<thead>
<tr>
<th>Tissues</th>
<th>0.5 hour</th>
<th>1 hour</th>
<th>2 hours block</th>
<th>4 hours</th>
<th>24 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent injected dose/g (%ID/g)⁴</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor</td>
<td>0.91 ± 0.12</td>
<td>0.73 ± 0.15</td>
<td>0.54 ± 0.06</td>
<td>0.29 ± 0.09</td>
<td>0.45 ± 0.20</td>
</tr>
<tr>
<td>Blood</td>
<td>1.08 ± 0.22</td>
<td>0.35 ± 0.14</td>
<td>0.20 ± 0.08</td>
<td>0.18 ± 0.04</td>
<td>0.16 ± 0.12</td>
</tr>
<tr>
<td>Brain</td>
<td>0.05 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.02 ± 0.01</td>
</tr>
<tr>
<td>Heart</td>
<td>0.57 ± 0.03</td>
<td>0.34 ± 0.17</td>
<td>0.35 ± 0.09</td>
<td>0.24 ± 0.02</td>
<td>0.36 ± 0.21</td>
</tr>
<tr>
<td>Lung</td>
<td>1.40 ± 0.07</td>
<td>0.96 ± 0.15</td>
<td>0.79 ± 0.07</td>
<td>0.70 ± 0.09</td>
<td>0.64 ± 0.20</td>
</tr>
<tr>
<td>Liver</td>
<td>2.30 ± 0.21</td>
<td>1.72 ± 0.94</td>
<td>1.68 ± 0.42</td>
<td>1.47 ± 0.53</td>
<td>1.65 ± 1.01</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.51 ± 0.07</td>
<td>0.40 ± 0.14</td>
<td>0.57 ± 0.31</td>
<td>0.52 ± 0.40</td>
<td>0.68 ± 0.44</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.54 ± 0.20</td>
<td>0.56 ± 0.26</td>
<td>0.36 ± 0.11</td>
<td>0.29 ± 0.10</td>
<td>1.14 ± 1.00</td>
</tr>
<tr>
<td>Kidneys</td>
<td>6.37 ± 1.44</td>
<td>4.32 ± 0.57</td>
<td>4.27 ± 0.84</td>
<td>4.12 ± 1.23</td>
<td>2.96 ± 0.31</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.23 ± 0.02</td>
<td>0.08 ± 0.03</td>
<td>0.06 ± 0.01</td>
<td>0.05 ± 0.01</td>
<td>0.07 ± 0.04</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.31 ± 0.10</td>
<td>0.14 ± 0.09</td>
<td>0.23 ± 0.05</td>
<td>0.18 ± 0.07</td>
<td>0.18 ± 0.09</td>
</tr>
<tr>
<td>Bone</td>
<td>0.26 ± 0.09</td>
<td>0.12 ± 0.05</td>
<td>0.15 ± 0.08</td>
<td>0.12 ± 0.05</td>
<td>0.12 ± 0.06</td>
</tr>
<tr>
<td>Percent injected dose (%ID)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intestines</td>
<td>2.05 ± 0.17</td>
<td>2.34 ± 1.3</td>
<td>3.1 ± 1.50</td>
<td>3.4 ± 0.40</td>
<td>3.3 ± 1.94</td>
</tr>
<tr>
<td>Urine</td>
<td>81.11 ± 1.20</td>
<td>88.4 ± 4.5</td>
<td>89.4 ± 3.60</td>
<td>87.8 ± 0.57</td>
<td>90.0 ± 5.40</td>
</tr>
<tr>
<td>Uptake ratio of tumor/normal tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor/blood</td>
<td>0.84</td>
<td>2.08</td>
<td>2.70</td>
<td>—</td>
<td>2.40</td>
</tr>
<tr>
<td>Tumor/muscle</td>
<td>3.95</td>
<td>9.12</td>
<td>9.00</td>
<td>6.40</td>
<td>5.40</td>
</tr>
<tr>
<td>Tumor/liver</td>
<td>0.39</td>
<td>0.42</td>
<td>0.32</td>
<td>0.27</td>
<td>0.20</td>
</tr>
</tbody>
</table>

⁴Data are presented as %ID/g ± SD except for intestines and urine, values for which are expressed as %ID ± standard deviation (n = 3).

*p = 0.03, significance comparison between the tumor uptake of radiolabeled peptide in the absence and presence of its nonradiolabeled counterpart at 2 hours p.i.

p.i., postinjection; SD, standard deviation.
### Table 3. Pharmacokinetic Studies of $^{64}$Cu-CB-TE2A-GSG-KCCYSL Using MDA-MB-435 Tumor-Bearing SCID Mice

<table>
<thead>
<tr>
<th>Tissues</th>
<th>0.5 hour</th>
<th>1 hour</th>
<th>2 hours</th>
<th>2 hours block</th>
<th>4 hours</th>
<th>24 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent injected dose/g (%ID/g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor</td>
<td>0.98 ± 0.31</td>
<td>0.64 ± 0.08</td>
<td>0.32 ± 0.17</td>
<td>0.16 ± 0.07b</td>
<td>0.17 ± 0.05</td>
<td>0.10 ± 0.03</td>
</tr>
<tr>
<td>Blood</td>
<td>1.18 ± 0.20</td>
<td>0.28 ± 0.12</td>
<td>0.05 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.011 ± 0.01</td>
</tr>
<tr>
<td>Brain</td>
<td>0.04 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.01 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.01 ± 0.01</td>
<td>0.007 ± 0.001</td>
</tr>
<tr>
<td>Heart</td>
<td>0.42 ± 0.31</td>
<td>0.15 ± 0.03</td>
<td>0.06 ± 0.02</td>
<td>0.05 ± 0.03</td>
<td>0.07 ± 0.01</td>
<td>0.012 ± 0.001</td>
</tr>
<tr>
<td>Lung</td>
<td>1.13 ± 0.16</td>
<td>0.46 ± 0.09</td>
<td>0.24 ± 0.02</td>
<td>0.20 ± 0.05</td>
<td>0.18 ± 0.02</td>
<td>0.05 ± 0.002</td>
</tr>
<tr>
<td>Liver</td>
<td>0.68 ± 0.11</td>
<td>0.52 ± 0.02</td>
<td>0.45 ± 0.05</td>
<td>0.37 ± 0.10</td>
<td>0.40 ± 0.03</td>
<td>0.29 ± 0.05</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.36 ± 0.11</td>
<td>0.20 ± 0.08</td>
<td>0.12 ± 0.06</td>
<td>0.10 ± 0.05</td>
<td>0.10 ± 0.01</td>
<td>0.01 ± 0.003</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.25 ± 0.08</td>
<td>0.18 ± 0.10</td>
<td>0.13 ± 0.06</td>
<td>0.15 ± 0.02</td>
<td>0.21 ± 0.12</td>
<td>0.03 ± 0.001</td>
</tr>
<tr>
<td>Kidneys</td>
<td>7.11 ± 0.75</td>
<td>6.72 ± 0.91</td>
<td>6.43 ± 1.56</td>
<td>6.94 ± 1.47</td>
<td>5.96 ± 0.89</td>
<td>3.18 ± 0.23</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.21 ± 0.07</td>
<td>0.06 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.05 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.007 ± 0.001</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.32 ± 0.11</td>
<td>0.14 ± 0.04</td>
<td>0.05 ± 0.01</td>
<td>0.02 ± 0.00</td>
<td>0.05 ± 0.01</td>
<td>0.04 ± 0.001</td>
</tr>
<tr>
<td>Bone</td>
<td>0.20 ± 0.05</td>
<td>0.07 ± 0.02</td>
<td>0.04 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.04 ± 0.01</td>
<td>0.03 ± 0.001</td>
</tr>
<tr>
<td>Percent injected dose (%ID)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intestines</td>
<td>1.02 ± 0.19</td>
<td>2.0 ± 2.10</td>
<td>0.75 ± 0.07</td>
<td>0.73 ± 1.27</td>
<td>1.3 ± 1.90</td>
<td>1.0 ± 1.14</td>
</tr>
<tr>
<td>Urine</td>
<td>78.2 ± 9.20</td>
<td>91.2 ± 3.74</td>
<td>95.2 ± 0.48</td>
<td>93.7 ± 4.30</td>
<td>95.3 ± 1.40</td>
<td>98.0 ± 2.40</td>
</tr>
</tbody>
</table>

Notes:
- *p = 0.027*, significance comparison between the tumor uptake of radiolabeled peptide in the absence and presence of its nonradiolabeled counterpart at 2 hours p.i.

### Table 4. Pharmacokinetic Studies of $^{64}$Cu-NO2A-GSG-KCCYSL Using MDA-MB-435 Tumor-Bearing SCID Mice

<table>
<thead>
<tr>
<th>Tissues</th>
<th>0.5 hour</th>
<th>1 hour</th>
<th>2 hours</th>
<th>2 hours block</th>
<th>4 hours</th>
<th>24 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent injected dose/g (%ID/g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor</td>
<td>0.78 ± 0.03</td>
<td>0.64 ± 0.04</td>
<td>0.61 ± 0.06</td>
<td>0.32 ± 0.09b</td>
<td>0.43 ± 0.02</td>
<td>0.1 ± 0.01</td>
</tr>
<tr>
<td>Blood</td>
<td>1.29 ± 0.09</td>
<td>0.33 ± 0.11</td>
<td>0.08 ± 0.01</td>
<td>0.10 ± 0.04</td>
<td>0.05 ± 0.02</td>
<td>0.01 ± 0.01</td>
</tr>
<tr>
<td>Brain</td>
<td>0.05 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.01 ± 0.001</td>
<td>0.00 ± 0.000</td>
</tr>
<tr>
<td>Heart</td>
<td>0.40 ± 0.05</td>
<td>0.16 ± 0.06</td>
<td>0.04 ± 0.01</td>
<td>0.08 ± 0.02</td>
<td>0.04 ± 0.02</td>
<td>0.07 ± 0.02</td>
</tr>
<tr>
<td>Lung</td>
<td>1.21 ± 0.08</td>
<td>0.49 ± 0.07</td>
<td>0.22 ± 0.08</td>
<td>0.34 ± 0.07</td>
<td>0.15 ± 0.06</td>
<td>0.10 ± 0.03</td>
</tr>
<tr>
<td>Liver</td>
<td>0.90 ± 0.09</td>
<td>0.55 ± 0.07</td>
<td>0.48 ± 0.05</td>
<td>0.57 ± 0.20</td>
<td>0.34 ± 0.10</td>
<td>0.27 ± 0.05</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.41 ± 0.07</td>
<td>0.19 ± 0.11</td>
<td>0.11 ± 0.05</td>
<td>0.11 ± 0.05</td>
<td>0.08 ± 0.05</td>
<td>0.07 ± 0.02</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.37 ± 0.04</td>
<td>0.18 ± 0.03</td>
<td>0.14 ± 0.04</td>
<td>0.20 ± 0.10</td>
<td>0.13 ± 0.03</td>
<td>0.10 ± 0.05</td>
</tr>
<tr>
<td>Kidneys</td>
<td>7.87 ± 0.96</td>
<td>6.51 ± 0.63</td>
<td>4.23 ± 1.00</td>
<td>6.70 ± 0.89</td>
<td>1.37 ± 0.28</td>
<td>0.68 ± 0.07</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.20 ± 0.05</td>
<td>0.06 ± 0.02</td>
<td>0.01 ± 0.01</td>
<td>0.01 ± 0.01</td>
<td>0.01 ± 0.01</td>
<td>0.01 ± 0.00</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.34 ± 0.09</td>
<td>0.10 ± 0.08</td>
<td>0.09 ± 0.03</td>
<td>0.05 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.03 ± 0.01</td>
</tr>
<tr>
<td>Bone</td>
<td>0.08 ± 0.05</td>
<td>0.04 ± 0.05</td>
<td>0.04 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.02 ± 0.01</td>
<td>0.01 ± 0.01</td>
</tr>
<tr>
<td>Percent injected dose (%ID)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intestines</td>
<td>1.2 ± 0.13</td>
<td>1.1 ± 0.27</td>
<td>1.06 ± 0.14</td>
<td>1.30 ± 0.60</td>
<td>1.33 ± 0.35</td>
<td>0.5 ± 0.10</td>
</tr>
<tr>
<td>Urine</td>
<td>84.4 ± 1.93</td>
<td>90.1 ± 4.04</td>
<td>96.0 ± 0.15</td>
<td>93.9 ± 1.06</td>
<td>96.7 ± 0.13</td>
<td>98.1 ± 0.14</td>
</tr>
</tbody>
</table>

Notes:
- *p = 0.027*, significance comparison between the tumor uptake of radiolabeled peptide in the absence and presence of its nonradiolabeled counterpart at 2 hours p.i.
between $^{64}$Cu-NO2A- and $^{64}$Cu-CB-TE2A-peptides were comparable and did not significantly differ ($p > 0.05$).

Blocking studies were performed with 100 μg of respective nontarget radiolabeled peptides 15 minutes before the injection of the radiolabeled peptides in tumor mice ($n = 3$). As a positive control, another set of mice ($n = 3$) was injected with respective radiolabeled peptides only. The results demonstrated that tumor uptake of radiolabeled peptide was blocked by 46% (DO3A-peptide, $p = 0.03$), 50% (CB-TE2A-peptide, $p = 0.024$), and 48% (NO2A-peptide, $p = 0.027$), respectively (Tables 2–4).

It is well known that high and persistent renal retention of radiolabeled peptides is a concern when designing receptor-targeted radiopharmaceuticals. In an attempt to study an agent that could interfere with kidney retention of the radiolabeled peptides, albumin fragments were used as inhibiting agents. The renal uptake of the radiolabeled peptides with and without albumin fragments (3–50 kDa) is shown in Figure 4. The kidney retention of the radiolabeled peptides with $^{64}$Cu-DO3A-, $^{64}$Cu-CB-TE2A-, and $^{64}$Cu-NO2A-(GSG)-KCCYSL was blocked in the presence of albumin fragments by 29%, 47%, and 47.5% ($n = 3$ each, $p \leq 0.05$), respectively.

Observations from small animal microPET experiments performed in SCID mice bearing MDA-MB-435 tumors at different times after intravenous injection of 12.0 MBq of each $^{64}$Cu-DO3A-, $^{64}$Cu-CB-TE2A-, and $^{64}$Cu-NO2A-(GSG)-KCCYSL were depicted in Figure 4. All the images were acquired at 2 hours p.i., of the radiolabeled peptides. Tumors could be easily visualized with radiolabeled peptides. For $^{64}$Cu-DO3A-peptide, the abdominal uptake and retention appeared high compared with $^{64}$Cu-CB-TE2A- and $^{64}$Cu-NO2A-peptides, which showed relatively less retention in the gastrointestinal tract and liver. A more notable difference in retention was observed in liver tissue for the $^{64}$Cu-DO3A-peptide, which was higher compared with $^{64}$Cu-CB-TE2A- or $^{64}$Cu-NO2A-KCCYSL, which agrees with the biodistribution data. Substantial uptake of all radiolabeled peptides in the kidneys was evident, indicating that these tracers are mainly excreted through the renal route.

**Discussion**

Our study demonstrates that a phage derived peptide, KCCYSL, that binds the extracellular domain of EGFR-2, once synthesized with a bi-functional chelator and radiolabeled with $^{64}$Cu, can be developed into a PET imaging agent for detection of breast tumors in vivo. Though other groups have reported peptides derived from phage display that bind EGFR-2, our studies are the first to demonstrate in vivo in a animal model that an EGFR-2 targeting peptide selected by phage display can be exploited as an SPECT or PET radiotargeting agent.

DOT3A-(GSG)-KCCYSL, CB-TE2A-(GSG)-KCCYSL, and NO2A-(GSG)-KCCYSL were synthesized and efficiently radiolabeled with $^{64}$Cu. One potential problem with cysteine-containing peptide(s) in aqueous buffers especially at neutral or alkaline pH is the oxidation of its thiol group to form disulfide bonds during radiolabeling reactions. Though the oxidation may be minimal in acidic pH (as in DO3A labeling), the chances are relatively high in near neutral pH such as the reaction conditions used in CB-TE2A and NO2A. To overcome this situation, the reaction buffers were extensively purged with nitrogen to keep oxygen levels minimal and also contained reducing agent TCEP to prevent the formation of disulfide bonds.

All the radiolabeled peptides bound to EGFR-2 expressing MDA-MB-435 breast carcinoma cells, whereas minimal binding was observed with normal mammary cells (184A1). MDA-MB-435 human breast carcinoma cells were originally isolated from a pleural effusion of a woman with metastatic breast adenocarcinoma. Rae et al. speculated in 2004 that the original MDA-MB-435 cancer cells were lost early after their establishment and found to be identical to the M-14 melanoma cell line. However, a recent report based on the different origin of these cell lines indicated that both MDA-MB-435 and M-14 cell lines are consistent with MDA-MB-435 breast cancer origin and that some poorly differentiated breast tumors can exhibit lineage infidelity and express markers associated with both epithelial and melanomas. Given this, the MDA-MB-435 breast carcinoma cell line has been widely used as a breast carcinoma model and remains one of the most reliable in vivo models of human breast cancer.

*In vitro* competition studies with unlabeled peptides demonstrated specificity of the radiolabeled peptide for breast carcinoma cells. Comparable binding affinities were noted with the three radiolabeled peptides. One would anticipate that binding affinity differences between the peptides may arise due to the use of different chelators. Previous studies with somatostatin receptor targeting DOTA-[Tyr3]-octreotide peptide analogs suggested that relatively small changes in a radiolabeled peptide, such as altering the chelator, can markedly change the receptor binding profile.

---

**FIG. 3.** Renal blocking studies with bovine serum albumin fragments. Albumin fragments (200 μg) were preinjected in the mice 5 minutes before the injection of radiolabeled peptides (0.185 MBq). The kidney uptake of the radioligands in mice with and without albumin fragments was measured in a $\gamma$-counter. Inhibition in the uptake of $^{64}$Cu-DO3A-(GSG)-KCCYSL (29%, $p = 0.037$), $^{64}$Cu-CB-TE2A-(GSG)-KCCYSL (47%, $p = 0.02$), and $^{64}$Cu-NO2A-(GSG)-KCCYSL (48%, $p = 0.032$) in the presence of albumin fragments are shown.
On the contrary, we did not observe any marked changes in the binding affinity profile of all three radiolabeled peptides tested to bind the breast carcinoma cells.

Comparative in vivo studies of $^{64}$Cu-DO3A-, $^{64}$Cu-CB-TE2A-, and $^{64}$Cu-NO2A- (GSG)-KCCYSL indicated reasonable tumor uptake of these peptides. $^{64}$Cu-CB-TE2A-(GSG)-KCCYSL, which had slower disappearance for the same time period (Tables 2 and 3). The delayed tumor tissue disappearance pattern of the $^{64}$Cu-DO3A-radioconjugate could be due to a trapping mechanism, such as transchelation of the radiometal from the chelator to intracellular protein(s).\(^{22,26,40}\) Moreover, significant transchelation of the $^{64}$Cu-DO3A-peptide to serum proteins occurs in blood,\(^{23,41}\) and the protein-bound $^{64}$Cu form may be transported back into the blood, which over time decreases target tissue:blood ratios.

All the radiolabeled peptides demonstrated significant blood disappearance rates, whereas the liver clearance was modest with relatively more retention of $^{64}$Cu-DO3A- compared with $^{64}$Cu-CB-TE2A and $^{64}$Cu-NO2A peptides. Unstable copper compounds in vivo (e.g., DO3A-peptides) are known to exhibit high retention in the liver that could be likely due to transchelation.\(^{42}\) The use of the $^{64}$Cu-DO3A chelation system can result in release of uncoordinated $^{64}$Cu by decomposition in the blood or transchelation in the liver, resulting in elevated uptake in liver tissue.\(^{23,41}\) On the other hand, CB-TE2A and NO2A chelator-peptides demonstrated less transchelation of the bound metal. Boswell et al. observed that the $^{64}$Cu-labeled chelator CB-TE2A during biodistribution studies in normal rats underwent significantly less transchelation in liver.\(^{25}\) In this study, it was shown that transchelation of $^{64}$Cu from $^{64}$Cu-DOTA was $39\% \pm 1\%$ at 1 hour, whereas transchelation of $^{64}$Cu from $^{64}$Cu-CB-TE2A was $12\% \pm 7\%$ for the same time period.\(^{25}\) Also, previous studies indicated that the injection of $[^{64}\text{Cu}]\text{Cu}^{2+}$ alone in mice resulted in half the injected dose ($\sim 54\%$) concentrated in the liver after 2 hours.\(^{43}\) Also, oral administration of copper acetate in tumor-bearing mice revealed the accumulation of copper in liver ($\sim 62.1\,\text{mg/g tissue}$) and kidneys ($\sim 4.8\,\text{mg/g tissue}$).\(^{43}\) Studies with $^{64}$Cu-NO2A-RGD-bombesin peptide uptake resulted in less uptake in the liver, compared to $^{64}$Cu tracers\(^{42}\) suggesting the high kinetic stability of the radiotracer. Another study with $^{64}$Cu-NO2A-bombesin analogs also reported the stability of NO2A peptides in vivo.\(^{28}\)

Nonspecific accumulation of radioactivity in the kidneys is often associated with the use of radiolabeled peptides in vivo.\(^{44}\) The kidney retention of copper KCCYSL peptides was found to be substantially high. Similar kidney retention of peptides with $^{64}$Cu-labeled azamacrocycles, including that of $^{64}$Cu-CB-TE2A-Y3-TATE and $^{64}$Cu-CB-TE2A-somatostatin receptor subtype 2 selective antagonist (sst2-ANT), was previously reported.\(^{25,45}\) Recent studies indicated that administering albumin fragments could reduce the renal uptake of radiolabeled peptides.\(^{33}\) Since only a small fraction of total albumin passes through the glomerular membrane, it was hypothesized that the use of albumin fragments could competitively inhibit the uptake of radiolabeled peptides in the kidneys.\(^{33}\) In the present study, biodistribution studies with an attempt to block the in vivo kidney uptake of $^{64}$Cu-DO3A-, $^{64}$Cu-CB-TE2A-, and $^{64}$Cu-NO2A-(GSG)-KCCYSL in the presence of albumin fragments resulted in a partial inhibition in the uptake of radiotracers by the kidneys.

**FIG. 4.** MicroPET/CT of MDA-MB-435 tumor-bearing mice. $^{64}$Cu-DO3A-(GSG)-KCCYSL, $^{64}$Cu-CB-TE2A-(GSG)-KCCYSL, or $^{64}$Cu-NO2A-(GSG)-KCCYSL 12.0 (MBq) each, was injected into the tail vein of SCID mice bearing MDA-MB-435 tumor xenograft. Imaging was acquired 2 hours postinjection, of the radiolabeled peptides in a PET scanner. The PET images were fused with conventional microCT images to validate regions of increased radiolabeled peptide uptake. The figures depict PET/CT images with (A) $^{64}$Cu-DO3A-(GSG)-KCCYSL; (B) $^{64}$Cu-CB-TE2A-(GSG)-KCCYSL; and (C) $^{64}$Cu-NO2A-(GSG)-KCCYSL (t, tumor; l, liver; k, kidney; i, intestine). CT, computed tomography; PET, positron emission tomography.
Similar to radiolabeled GSG-KCCYSL peptides, corresponding nonradiolabeled peptides presumably undergo faster blood clearance, and demetallation from these peptides may also occur in the liver. This presumably could have been attributed to partial blocking of tumoral uptake of the radiolabeled peptides in the presence of their nonradiolabeled counterparts during biodistribution studies. Thus, lack of longer residence time of the competing molecule and its uptake in nontarget tissues including kidney could result in less efficient blocking of the radioligand uptake in tumor unlike large molecules such as antibodies, which have much longer circulation times in vivo.66

Small-animal PET/CT studies with all three radiolabeled peptides demonstrated reasonable tumor uptake and retention. In spite of similar tumor uptake by these peptides, differences in uptake and retention of these compounds in nontarget tissues were found. For the 64Cu-DO3A-peptide, the image revealed significant activity in the liver, gastrointestinal tract, and the kidneys. The image obtained with 64Cu-CB-TE2A and 64Cu-NO2A-peptides, however, demonstrated relatively reduced activity in the liver and the gastrointestinal tract with comparable retention in the kidneys. Likewise, biodistribution and imaging studies with 64Cu-CB-TE2A-Y3-TATE, a somatostatin receptor targeting peptide, showed low uptake in liver and blood and more in the kidneys.31 Recent studies with 64Cu-CB-TE2A-ReCCMSH(Arg11), a melanocortin receptor targeting peptide, demonstrated reduced uptake in liver and blood and a modest uptake in the kidneys compared with 64Cu-DOTA-ReCCMSH(Arg11).47 Taken together, 64Cu-CB-TE2A- and 64Cu-NO2A-peptides demonstrated better tumor-to-background ratios and nontarget tissue clearance compared with the DO3A-peptide. Overall, the cross-bridged cyclam chelator CB-TE2A and NOTA exhibit comparable stability, thus enabling efficient 64Cu-radiopharmaceutical applications with biological targeting molecules such as the KCCYSL peptide.

Conclusions

The peptides 64Cu-DO3A-(GSG)-KCCYSL, 64Cu-CB-TE2A-(GSG)-KCCYSL, and 64Cu-NO2A-(GSG)-KCCYSL were evaluated as agents for PET imaging of breast carcinoma. The 64Cu-stabilization properties of CB-TE2A and NOTA compared with those of DOTA resulted in improved blood disappearance and lower retention in liver and the gastrointestinal tract, with improved tumor-to-nontarget tissue ratios for 64Cu-CB-TE2A- and 64Cu-NO2A-GSG-KCCYSL. Thus, CB-TE2A and NO2A-peptides appear to be better candidates for application as diagnostic PET agents for EGFR-2 expressing breast cancers.

Acknowledgments

This work was supported by awards from the National Institutes of Health, (P50CA103130-01, 1R-21CA137239-01A1, and 2 R01 CA093375) and in part by a Merit Review Award from the Veterans Administration (SLD). We thank Dr. Said Figueroa for his help with imaging studies. We also thank the VA Biomolecular Imaging Center (BIC) at the Harry S. Truman Memorial Veteran’s Hospital. We acknowledge Lisa Watkinson and Terry Carmack for performing animal experiments and Marie Dickerson for technical help.

Disclosure Statement

No competing financial interests exist.

References
